

# CNB-001 reduces paraplegia in rabbits following spinal cord ischemia

Paul A. Lapchak<sup>1,\*</sup>, Paul D. Boitano<sup>2</sup>, Rene Bombien<sup>2</sup>, Daisy Chou<sup>2</sup>, Margot Knight<sup>2</sup>, Anja Muehle<sup>2</sup>, Mihaela Te Winkel<sup>2</sup>, Ali Khoynzhad<sup>2</sup>

<sup>1</sup> Neurocore LLC, Pomona, CA, USA

<sup>2</sup> Department of Surgery, Memorial Care Health System, Long Beach, CA, USA

## Abstract

Spinal cord ischemia associated with trauma and surgical procedures including thoraco-abdominal aortic aneurysm repair and thoracic endovascular aortic repair results in devastating clinical deficits in patients. Because spinal cord ischemia is inadequately treated, we studied the effects of [4-((1E)-2-(5-(4-hydroxy-3-methoxystyryl)-1-phenyl-1H-pyrazoyl-3-yl) vinyl)-2-methoxy-phenol)] (CNB-001), a novel curcumin-based compound, in a rabbit SCI model. CNB-001 is known to inhibit human 5-lipoxygenase and 15-lipoxygenase and reduce the ischemia-induced inflammatory response. Moreover, CNB-001 can reduce the level of oxidative stress markers and potentiate brain-derived neurotrophic factor and brain-derived neurotrophic factor receptor signaling. The Tarlov scale and quantal analysis technique results revealed that CNB-001 administered as an intravenous dose (bolus) 30 minutes prior to spinal cord ischemia improved the behaviors of female New Zealand White rabbits. The improvements were similar to those produced by the uncompetitive N-methyl-D-aspartate receptor antagonist memantine. At 48 hours after aortic occlusion, there was a 42.7% increase ( $P < 0.05$ ) in tolerated ischemia duration ( $n = 14$ ) for rabbits treated with CNB-001 ( $n = 16$ ), and a 72.3% increase for rabbits treated with the positive control memantine ( $P < 0.05$ ) ( $n = 23$ ) compared to vehicle-treated ischemic rabbits ( $n = 22$ ). CNB-001 is a potential important novel treatment for spinal cord ischemia induced by aortic occlusion. All experiments were approved by the CSMC Institutional Animal Care and Use Committee (IACUC #4311) on November 1, 2012.

**Key Words:** curcumin analog; spinal cord injury; spinal cord ischemia; thoraco-abdominal aortic aneurysm; thoracic endovascular aortic repair; motor function; neuroprotection; neurorepair

**Chinese Library Classification No.** R453; R744; R641

## Introduction

Spinal cord ischemia (SCI) is inadequately treated in the clinic due to the lack of efficacious therapeutic neuroprotective options (Lapchak et al., 2000a; Lapchak, 2004; Arbo et al., 2018) and high cost of drug research and development (Lapchak and Zhang, 2017). SCI and its sequelae are the most devastating and feared complications during the perioperative phase in patients undergoing open thoraco-abdominal aortic aneurysm (TAAA) repair and thoracic endovascular aortic repair (TEVAR) (Shaw, 1986; Skillman, 1986; Lintott et al., 1998; Rectenwald et al., 2002; Terada et al., 2004; Jacobs et al., 2007; Bicknell et al., 2009; Min et al., 2010; Uchida, 2014; Fleissner et al., 2015; Nardone et al., 2016; Miranda et al., 2018). Aortic surgery may lead to athero-embolic stroke (Nardone et al., 2016) and long-term disability and even result in high morbidity and mortality (Kornberger et al., 2018; Agostinelli et al., 2019; Stern et al., 2019).

Paraplegia resulting from TEVAR or TAAA has been reportedly to be associated with ischemia and a prolonged inflammatory response (Delamarter and Coyle, 1999; Fu and Tummala, 2005; Nardone et al., 2016). Evidence exists that the incidence rate of paraplegia after TEVAR or TAAA is highly variable, it is estimated that 3–22% of patients subjected to TEVAR or TAA will become paraplegic during or after surgical procedures, and the prognosis is highly poorer in female patients than in male patients (Shaw, 1986; Skillman, 1986; Lintott et al., 1998; Rectenwald et al., 2002; Terada et al., 2004;

Jacobs et al., 2007; Bicknell et al., 2009; Min et al., 2010; Uchida, 2014; Fleissner et al., 2015; Nardone et al., 2016).

For aortic surgery-caused SCI, the currently available therapeutic options include standard corticosteroid (methylprednisolone) administration to reduce chronic inflammation (Raiten et al., 2015a, b; Nardone et al., 2016) and the potential use of stem cell therapy to attempt to repair and regenerate affected neuronal populations (Curtis et al., 2018; Xie et al., 2018; Zhang, 2018; Zhu et al., 2018; Tsuji et al., 2019). Both of these two options are still in their infancy and have limited efficaciousness and clinical utility. It is important to note that neuroprotective strategies for SCI have not been abandoned by the research community, and are currently being studied in detail in relevant models because of the potential clinical use of such agents (Hilton et al., 2017; Sámano and Nistri, 2019; Cai et al., 2018; Chen et al., 2018; Cheng et al., 2018; Ishii et al., 2018; Jacobs and Lovejoy, 2018; Ortmann and Hellenbrand, 2018; Ruzicka et al., 2018; Springer et al., 2018a, b; Zhang et al., 2018).

We have synthesized and extensively characterized (*in vitro* and *in vivo*) curcumin-based pleiotropic compound CNB-001 [4-((1E)-2-(5-(4-hydroxy-3-methoxystyryl)-1-phenyl-1H-pyrazoyl-3-yl)vinyl)-2-methoxy-phenol)] (Lapchak, 2011; Lapchak and Boitano, 2014; Panzhinskiy et al., 2014; Lapchak et al., 2019). CNB-001 is a very promising drug candidate, a neuroprotective and cytoprotective molecule (Liu et al., 2008; Lapchak, 2011; Lapchak et al., 2011,

## \*Correspondence to:

Paul A. Lapchak, PhD, FAHA,  
palapchak@gmail.com.

## orcid:

0000-0003-4413-7554  
(Paul A. Lapchak)

doi: 10.4103/1673-5374.262598

Received: January 11, 2019

Accepted: May 11, 2019

2019; Jayaraj et al., 2013, 2014a, b; Lapchak and Boitano, 2014; Panzhinskiy et al., 2014), in part due to its anti-inflammatory, anti-oxidant, anti-excitotoxic and neurotrophic-like activities, which are related to brain-derived neurotrophic factor and tyrosine receptor kinase (Trk).

In this study, we described the novel application of CNB-001 in the rabbit SCI model (RSCIM) that was developed by our group to test compounds for their efficacy to reduce the behavioral consequence of occlusion of the infrarenal aorta (Waterford et al., 2015). This study was conducted in consistence with currently applicable standardized research guidelines (Landis et al., 2012; Lapchak, 2013; Lapchak and Zhang, 2018). We studied the potential benefit of CNB-001, compared to a standardized positive control, the noncompetitive N-methyl-D-aspartate receptor (NMDA) antagonist, memantine (Chen et al., 1992; Chen and Lipton, 2005; Lipton, 2005; Lapchak, 2006). The large animal model that we used in this translational study has the advantage of reproducing paraplegia resulting from SCI induced by aortic occlusion, similar to the clinical situation (Lapchak et al., 2000a; Min et al., 2010; Ullery et al., 2011b, c), making it a suitable translationally relevant research and drug development tool.

## Materials and Methods

### Animals and surgery

Female New Zealand white rabbits (3.5–4 kg, 6 months old) acquired from IFPS, Norco, CA, USA were included in this study. All animals were quarantined for a minimum of 3 days, and were supplied food and water *ad libitum* while animals were maintained in an enriched environment prior to experimental use. All experiments were approved by the CSMC Institutional Animal Care and Use Committee (IACUC #4311) on November 1, 2012.

The rabbits were randomized to the following four groups:

Control group 1 (for memantine SCI group): normal animals were intravenously injected with 70% saline ( $n = 22$ ).

Control group 2 (for CNB-001 SCI group): SCI animals were intravenously injected with solutol HS15 in 70% saline 30 minutes prior to aortic occlusion ( $n = 14$ ).

CNB-001 SCI group: SCI animals were intravenously injected with CNB-001 (10 mg/kg) 30 minutes prior to aortic occlusion ( $n = 16$ ).

Memantine SCI group: SCI animals were intravenously injected with memantine (20 mg/kg) 30 minutes prior to aortic occlusion ( $n = 23$ ).

### Drug preparation and administration

CNB-001 was synthesized by AQ BioPharma Co., Ltd. (Shanghai, China) as described previously (Lapchak et al., 2019). For intravenous administration, the test drug, CNB-001 (10 mg/mL) was dissolved in 30% solutol HS15 in 70% saline, whereas the positive control, memantine (20 mg/kg (10 mg/mL); Sigma Inc., St. Louis, MO, USA) was dissolved in saline. Both drugs were maintained at 37–39°C prior to intravenous injection (slow bolus) (see **Figure 1** for experimental design).

### Rabbit spinal cord ischemia models (RSCIM)

The SCI procedure achieved by aortic occlusion using balloon inflation was described in detail elsewhere (Waterford et al., 2015).

### Motor function assessment

In the treatment group, rabbit behavior was rated by the author MTW at 4, 24, and 48 hours using the standard Tarlov scoring scale (Sirlak et al., 2008). If the animal was considered paraplegic with a Tarlov score of 0 or 1 at 24 hours, it was euthanized by intravenous injection of a lethal amount of pentobarbital (Virbac Animal Health, Fort Worth, TX, USA) on day 1 post-surgery as per the recommendation of Institutional Animal Care and Use Committee (IACUC). All other animals were euthanized after the 48 hour rating with a lethal intravenous injection of pentobarbital.

Briefly, Tarlov scale (Tarlov et al., 1953; Tarlov, 1954, 1955, 1972; Tarlov and Herz, 1954; Tarlov and Klinger, 1954; Gelfan and Tarlov, 1955, 1956) was defined as follows: a score of 0, paraplegia with no lower extremity function; 1, poor lower extremity function and weak antigravity movement; 2, some lower extremity function with good antigravity strength, but unable to draw legs under body or hop; 3, the ability to draw legs under body and hop, but abnormal function; 4, normal motor function.

The quantal analysis technique was used for statistical analysis. We utilized a wide range of ischemia durations in each treatment group as described in detail previously (Lapchak et al., 2000a, 2001; Lapchak, 2004).

To encompass population response, we designated Tarlov scores of 3–4 as normal behavior, while Tarlov scores of 1–2 were designated as abnormal. We plotted quantal analysis curves of ischemia duration *versus* behavior (normal or abnormal as defined above), which allowed us to calculate the  $P_{50}$  value in minute. A curve was produced for each treatment condition. A statistically significant increase in  $P_{50}$  value of the drug-treated group compared to a control group indicated beneficial neuroprotection, as measured by behavioral improvement in the rabbit SCI study population.

### RIGOR, power and statistical analysis

This study was conducted in a randomized and blinded manner as per stroke therapy academic industry roundtable (STAIR) (STAIR, 1999; Fisher, 2003) and RIGOR guidelines and criteria (Lapchak and Zhang, 2018). Rabbits were randomized to treatment groups before the surgical procedure. The allocation was concealed by an independent party technical associate, and was not revealed until all analyses were completed.

Power analysis of the quantal dose-response curves for rabbits indicates that, assuming  $\alpha = 0.05$ , a standard deviation of 25%, and a sample size of 14 animals per treatment group, we had 90% power to detect a 50% change in mean  $P_{50}$  values. Quantal analysis curve  $P_{50}$  values were calculated using an iterative curve-fitting algorithm as described previously (Lapchak et al., 2000a, b, 2001, 2003; Lapchak, 2004). Quantal analysis data are presented as  $P_{50}$  (mean  $\pm$  SEM) in

minutes for the number of rabbits in each group (*n*) for the RSCIM. Data were analyzed for significance using the unpaired *t*-test (MedCalc Version 9.4.1.0; MedCalc Software, Mariakerke, Belgium).

## Results

### CNB-001 reduces paraplegia incidence in female rabbits following SCI

In this study, six rabbits were excluded due to the absence of paraplegia verification after balloon inflation, and additional five rabbits were excluded because of reperfusion-injury pain when rabbits vocalized.

To determine if CNB-001 would be efficacious in the RSCIM, we studied the effects of treatment with either intravenous CNB-001 (10 mg/kg) or memantine (20 mg/kg) (Chen et al., 1992; Chen and Lipton, 2005; Lapchak, 2006; Lipton, 2006), a noncompetitive low affinity NMDA open-channel antagonist, on behavioral deficits of female rabbits following infrarenal aortic occlusion. In this study, memantine was first used as a positive control to demonstrate that behavioral improvement could be measured using Tarlov scores and quantal analysis.

As shown in **Figure 2**, there was a 46% increase in the  $P_{50}$  value ( $19.38 \pm 2.03$  minutes,  $n = 16$ ) for CNB-001 pre-treated rabbits compared to the memantine SCI group ( $P_{50} = 13.58 \pm 0.90$  minutes,  $n = 14$ ;  $P < 0.05$ ). As shown in **Figure 3**, memantine produced a 72% increase in ischemia duration ( $P_{50}$  value =  $22.52 \pm 2.98$  minutes,  $n = 23$ ) in rabbits with a paraplegic Tarlov score of 1–2 (See **Table 1** for raw data) compared to the memantine SCI group ( $13.07 \pm 2.12$  minute,  $n = 22$ ;  $P < 0.05$ ). The  $P_{50}$  values for CNB-001 and memantine were not statistically different ( $P > 0.05$ ).

## Discussion

In this proof-of-concept translational study, we used a previously established method (Waterford et al., 2015) to produce ischemia by inflating a Fogarty balloon in the infrarenal aorta of rabbits. This procedure resulted in paraplegia as measured by the loss of left lower extremity blood pressure and the disappearance of lower extremity motor potential. There were no discernable changes in the extent of blood pressure decrease or paraplegia between the four groups studied. No significant difference in morbidity or mortality was observed among the four groups.


The primary strength of this work is the translational value of utilizing the rabbit paraplegia model with quantal analysis to demonstrate the significant efficacy of the curcumin compound CNB-001 that effectively crosses the blood-brain barrier (Lapchak et al., 2019). Briefly, we found that intravenous CNB-001 administered pre-treatment, produced statistically significant clinical improvement in female rabbits, adding to a wealth of knowledge of the effects of CNB-001 in stroke and ischemia models (Lapchak et al., 2011, 2019). The pre-treatment regimen adopted for CNB-001 study in the RSCIM is justified, because the RSCIM that was developed parallels in some aspects SCI that results from modern surgical procedures, including TAAA repair and TEVAR (Shaw, 1986; Skillman, 1986; Lintott et al., 1998; Rectenwald et al., 2002; Terada et al., 2004; Jacobs et al., 2007; Bicknell et al., 2009; Min et al., 2010; Uchida, 2014; Fleissner et al., 2015; Nardone et al., 2016; Miranda et al., 2018).

TAAA repair and TEVAR are fraught with challenges that can possibly be overcome if a safe and efficacious neuroprotective therapy can be used prior to and/or concomitantly with difficult surgical procedures. Moreover, since aortic sur-


**Table 1** Raw quantal curve data for 30 minute pretreatment regimen

Occlusion time (minute)	Control		Memantine (20 mg/kg)		Occlusion time	Control		CNB-001 (10 mg/kg)	
	N	Ab	N	Ab		N	Ab	N	Ab
8	1	0	1	0	10	1	0	1	0
10	1	0	1	0	12	2	0	1	0
12	1	0	1	0	13	0	1	1	0
13	0	1	1	0	14	1	0	1	0
14	0	1	0	1	15	0	1	1	0
15	0	1	1	0	18	0	1	1	0
20	1	0	1	0	19	0	1	0	1
24	0	1	1	1	20	0	1	1	0
25	0	1	1	0	21	0	1	0	2
26	0	1	1	1	22	0	1	0	1
27	0	1	1	2	23	0	1	0	1
28	0	1	0	1	24	0	1	0	1
30	0	1	0	1	25	0	1	0	1
33	0	1	0	1	30	ND	ND	1	1
35	0	1	0	1					
40	0	1	0	1					
45	0	1	0	1					
50	0	1	0	1					
55	0	1	0	1					


N: Normal; Ab: abnormal; ND: not determined.



**Figure 1 Experimental design temporal profile.** Female rabbits underwent the aortic occlusion procedure for various durations as shown in the figure. Rabbits were pretreated by intravenous bolus of 10 mg/kg CNB-001/vehicle 30 minutes before aortic occlusion. Behavior was assessed at 24 and 48 hours. CNB-001: 4-((1E)-2-(5-(4-hydroxy-3-methoxystyryl)-1-phenyl-1H-pyrazoyl-3-yl) vinyl)-2-methoxy-phenol.



**Figure 2 CNB-001 pre-treatment prevents paraplegia in female rabbits subjected to aortic occlusion.** Rabbits were pretreated by intravenous vehicle (30% Solutol HS15 in saline,  $n = 14$ ) or CNB-001 (10 mg/mL,  $n = 16$ ) 30 minutes (min) before aortic occlusion. CNB-001 (red line, red X) significantly increased the  $P_{50}$  value (ischemia duration by 5.8 minutes) measured at 48 hours after aortic occlusion (unpaired  $t$ -test,  $*P < 0.05$ ) compared to vehicle control (black line, black circle), and improved rabbit behaviors. For the superimposed graphs, behaviorally normal animals are plotted on the y-axis at 0 and abnormal animals are plotted at 100. CNB-001: 4-((1E)-2-(5-(4-hydroxy-3-methoxystyryl)-1-phenyl-1H-pyrazoyl-3-yl) vinyl)-2-methoxy-phenol.



**Figure 3 Memantine pre-treatment prevents paraplegia in female rabbits subjected to aortic occlusion.** Female rabbits underwent the aortic occlusion procedure for various durations as shown in the figure. Rabbits were pretreated with intravenous either vehicle (saline, black line, black circle,  $n = 22$ ) or memantine (20 mg/kg; red line, red X,  $n = 23$ ) 30 minutes (min) before aortic occlusion. Memantine significantly increased the  $P_{50}$  value (ischemia duration by 9.45 minutes) measured at 48 hours after aortic occlusion (unpaired  $t$ -test,  $*P < 0.05$ ), and improved rabbit behaviors. For graphical analysis, normal animal data are plotted on the y-axis at 0 and abnormal animal data are plotted at 100.

gery can occasionally involve athero-embolic events (Nardone et al., 2016), the use of CNB-001 as demonstrated in both rabbits and primates (Lapchak et al., 2019) could potentially reduce the extent of clinical deficits in stroke patients.

In this study, CNB-001 was directly compared to memantine in parallel studies that required the use of two different vehicle control groups because of the differential solubility characteristics of CNB-001 and memantine. The data showed that the baseline  $P_{50}$  value for the vehicle control was not significantly different. Moreover, when compared to the appropriate vehicle control, CNB-001 increased  $P_{50}$  value by 42.7% and memantine increased  $P_{50}$  value by 72.3%. Clearly there were differences in the magnitude of the efficacy that may be dose-related. It is of importance to note that this proof-of-concept study utilized only single doses of both CNB-001 and memantine, and the doses were both selected based upon previous work done in our group (Lapchak, 2006; Lapchak et al., 2011, 2019). The selected dose of CNB-001 was previously shown to be efficacious in male rabbits, male non-human primates and male rats (data not shown). This study adds to the knowledge base for CNB-001 by demonstrating statistically significant efficacy in females. Based on this, both dose-response analysis for maximum efficacy following aortic occlusion and temporal analysis studies regarding pre- and post-treatment timing for maximum durability can be conducted once they are funded by NIH/NINDS or another funding agency. Moreover, complete gender analysis can be conducted.

Strong evidence exists that the pleiotropic properties of the molecule CNB-001 are extremely important (Liu et al., 2008; Lapchak, 2011; Lapchak et al., 2011, 2019; Jayaraj et al., 2013, 2014a, b; Lapchak and Boitano, 2014; Panzhinskiy et al., 2014) for neuroprotection. CNB-001 is reported to decrease the generation of reactive oxygen species, reduce the production of a variety of inflammatory mediators including tumor necrosis factor- $\alpha$  and interleukin-6, and attenuate deleterious membrane lipid peroxidation. CNB-001 also effectively preserves normal physiological mitochondrial membrane potential, which is important for cellular energy production and function. These characteristics of CNB-001 indicate that it would have utility in the treatment of ischemic diseases (Liu et al., 2008; Maher et al., 2010; Sharma et al., 2010; Lapchak, 2011; Lapchak et al., 2011, 2019; Wu et al., 2011; Jayaraj et al., 2013, 2014a, b; Valera et al., 2013; Lapchak and Boitano, 2014; Panzhinskiy et al., 2014). In addition, CNB-001 stimulates the production of brain-derived neurotrophic factor (*i.e.*, pro-survival neurotrophic factors) and activates the pathways involved in cytoprotection (Liu et al., 2008; Sharma et al., 2010; Lapchak et al., 2011, 2019; Wu et al., 2011; Valera et al., 2013). Future studies will elucidate the mechanisms involved in reduced functional deficits using the RSCIM.

CNB-001 can reduce behavioral dysfunction in the RSCIM (as shown in the current study), narrow the spread of ischemia (*i.e.*, infarct growth) in cynomolgus monkeys, and improve the clinical function of the rabbit small clot

embolic stroke model (RSCEM) (Lapchak et al., 2011, 2019) when administered either pre- or post-ischemia. It is promising to use a molecule like CNB-001 to halt the consequence of ischemic damage when provided to patients prior to TAAA repair and TEVAR where there is a high incidence of SCI, which can result in paraplegia (Svensson et al., 2003; Svensson, 2005; Dillavou and Makaroun, 2008; Ullery et al., 2011a, b, c). As hypothesized previously (Lapchak et al., 2019), it may be possible to “freeze” penumbra in patients in the field, immediately upon first contact of spinal cord injury (ischemia) patients or victims with emergency vehicle personnel, paramedics or medics (*i.e.*, athletes, football or soccer players as an example, car accident victims, enlisted military personnel), and ischemic stroke patients prior to current conventional reperfusion therapies (Bratane et al., 2011; Lapchak et al., 2019).

The current study showed that pretreatment with CNB-001 significantly reduced ischemia-induced paraplegia in female rabbits with SCI. The early effects of CNB-001 to interfere with the ischemic cascade following ischemia in the SCI model may in part be linked to its ability to counteract the deleterious effects of glutamate on cells (Liu et al., 2008; Lapchak et al., 2011) and to reduce the propagation of ischemia. CNB-001 is a valid candidate to treat ischemic disease and should be further pursued in well-designed clinical trials.

**Author contributions:** PAL: Study design and implementation and manuscript writing; PDB, MK, AK: study implementation and technical support; RB: study design and implementation and manuscript editing; DC: study design and implementation; MTW: study implementation and primary Tarlov ratings; AK: study design and implementation. All authors approved the final version of this manuscript.

**Conflicts of interest:** Funding for this project was provided by anonymous donors to support translational research. The authors declare no conflict of interest relating to the material presented in this Article. Its contents, including any opinions and/or conclusions expressed, are solely those of the authors.

**Financial support:** None.

**Institutional review board statement:** The study was approved by the CSMC Institutional Animal Care and Use Committee (IACUC #4311) on November 1, 2012.

**Copyright license agreement:** The Copyright License Agreement has been signed by all authors before publication.

**Data sharing statement:** Datasets analyzed during the current study are available from the corresponding author on reasonable request.

**Plagiarism check:** Checked twice by iThenticate.

**Peer review:** Externally peer reviewed.

**Open access statement:** This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-Non-Commercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

**Open peer reviewers:** Syoichi Tashiro, Keio University School of Medicine, Japan; Adriana Vizuete, Universidade Federal do Rio Grande do Sul Instituto de Ciencias Basicas da Saude, Brazil.

**Additional file:** Open peer review reports 1 and 2.

## References

- Agostinelli A, Carino D, Borrello B, Marcato C, Volpi A, Gherli T, Nicolini F (2019) Blunt traumatic injury to the thoracic aorta treated with thoracic endovascular aortic repair: a single-centre 20-year experience. *Interact Cardiovasc Thorac Surg* 28:17-22.
- Arbo BD, Ribeiro FS, Ribeiro MF (2018) Astrocyte neuroprotection and dehydroepiandrosterone. *Vitam Horm* 108:175-203.

- Bicknell CD, Riga CV, Wolfe JH (2009) Prevention of paraplegia during thoracoabdominal aortic aneurysm repair. *Eur J Vasc Endovasc Surg* 37:654-660.
- Bratane BT, Cui H, Cook DJ, Bouley J, Tymianski M, Fisher M (2011) Neuroprotection by freezing ischemic penumbra evolution without cerebral blood flow augmentation with a postsynaptic density-95 protein inhibitor. *Stroke* 42:3265-3270.
- Cai J, Sun Y, Yin Z, Wang D, Shi K, Fu Y, Cao X, Ge Y (2018) Analysis of FK506-mediated functional recovery and neuroprotection in a rat model of spinal cord injury indicates that EGF is modulated in astrocytes. *Exp Ther Med* 16:501-510.
- Chen C, Bai GC, Jin HL, Lei K, Li KX (2018) Local injection of bone morphogenetic protein 7 promotes neuronal regeneration and motor function recovery after acute spinal cord injury. *Neural Regen Res* 13:1054-1060.
- Chen HS, Lipton SA (2005) Pharmacological implications of two distinct mechanisms of interaction of memantine with N-methyl-D-aspartate-gated channels. *J Pharmacol Exp Ther* 314:961-971.
- Chen HS, Pellegrini JW, Aggarwal SK, Lei SZ, Warach S, Jensen FE, Lipton SA (1992) Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. *J Neurosci* 12:4427-4436.
- Cheng X, Zheng Y, Bu P, Qi X, Fan C, Li F, Kim DH, Cao Q (2018) Apolipoprotein E as a novel therapeutic neuroprotection target after traumatic spinal cord injury. *Exp Neurol* 299:97-108.
- Curtis E, Martin JR, Gabel B, Sidhu N, Rzesiewicz TK, Mandeville R, Van Gorp S, Leerink M, Tadokoro T, Marsala S, Jamieson C, Marsala M, Ciacci JD (2018) A first-in-human, phase I study of neural stem cell transplantation for chronic spinal cord injury. *Cell Stem Cell* 22:941-950.
- Delamarter RB, Coyle J (1999) Acute management of spinal cord injury. *J Am Acad Orthop Surg* 7:166-175.
- Dillavou ED, Makaroun MS (2008) Predictors of morbidity and mortality with endovascular and open thoracic aneurysm repair. *J Vasc Surg* 48:1114-1120.
- Fisher M (2003) Recommendations for advancing development of acute stroke therapies: Stroke Therapy Academic Industry Roundtable 3. *Stroke* 34:1539-1546.
- Fleissner F, Redwan A, Bisdas T, Boeck AL, Weissenborn K, Haverich A, Teebken OE, Pichlmaier M, Martens A (2015) Intraoperative changes in cerebrospinal fluid gas tensions reflect paraplegia during thoracoabdominal aortic surgery: a proof-of-principle study. *Vasc Endovascular Surg* 49:84-92.
- Fu ES, Tummala RP (2005) Neuroprotection in brain and spinal cord trauma. *Curr Opin Anaesthesiol* 18:181-187.
- Gelfan S, Tarlov IM (1955) Differential vulnerability of spinal cord structures to anoxia. *J Neurophysiol* 18:170-188.
- Gelfan S, Tarlov IM (1956) Physiology of spinal cord, nerve root and peripheral nerve compression. *Am J Physiol* 185:217-229.
- Hilton BJ, Moulson AJ, Tetzlaff W (2017) Neuroprotection and secondary damage following spinal cord injury: concepts and methods. *Neurosci Lett* 652:3-10.
- Ishii H, Petrenko AB, Sasaki M, Satoh Y, Kamiya Y, Tobita T, Furutani K, Matsuhashi M, Kohno T, Baba H (2018) Free radical scavenger edaravone produces robust neuroprotection in a rat model of spinal cord injury. *Brain Res* 1682:24-35.
- Jacobs KR, Lovejoy DB (2018) Inhibiting the kynurenine pathway in spinal cord injury: multiple therapeutic potentials? *Neural Regen Res* 13:2073-2076.
- Jacobs MJ, Mommertz G, Koeppl TA, Langer S, Nijenhuis RJ, Mess WH, Schurink GW (2007) Surgical repair of thoracoabdominal aortic aneurysms. *J Cardiovasc Surg (Torino)* 48:49-58.
- Jayaraj RL, Tamilselvam K, Manivasagam T, Elangovan N (2013) Neuroprotective effect of CNB-001, a novel pyrazole derivative of curcumin on biochemical and apoptotic markers against rotenone-induced SK-N-SH cellular model of Parkinson's disease. *J Mol Neurosci* 51:863-870.
- Jayaraj RL, Elangovan N, Manigandan K, Singh S, Shukla S (2014a) CNB-001 a novel curcumin derivative, guards dopamine neurons in MPTP model of Parkinson's disease. *Biomed Res Int* 2014:236182.
- Jayaraj RL, Elangovan N, Dhanalakshmi C, Manivasagam T, Essa MM (2014b) CNB-001, a novel pyrazole derivative mitigates motor impairments associated with neurodegeneration via suppression of neuroinflammatory and apoptotic response in experimental Parkinson's disease mice. *Chem Biol Interact* 220:149-157.
- Kornberger A, Petar R, El Beyrouiti H, Khalil M, Burck I, Halloum N, Beiras-Fernandez A, Vahl CF (2018) Repair of TEVAR-associated type A dissection in the elderly is possible with reasonable morbidity and mortality. *Vasc Endovascular Surg* 52:405-410.
- Landis SC et al. (2012) A call for transparent reporting to optimize the predictive value of preclinical research. *Nature* 490:187-191.
- Lapchak PA (2004) The neuroactive steroid 3-alpha-ol-5-beta-pregnan-20-one hemisuccinate, a selective NMDA receptor antagonist improves behavioral performance following spinal cord ischemia. *Brain Res* 997:152-158.
- Lapchak PA (2006) Memantine, an uncompetitive low affinity NMDA open-channel antagonist improves clinical rating scores in a multiple infarct embolic stroke model in rabbits. *Brain Res* 1088:141-147.
- Lapchak PA (2013) Recommendations and practices to optimize stroke therapy: developing effective translational research programs. *Stroke* 44:841-843.
- Lapchak PA, Boitano PD (2014) Effect of the pleiotropic drug CNB-001 on tissue plasminogen activator (tPA) protease activity in vitro: support for combination therapy to treat acute ischemic stroke. *J Neurol Neurophysiol* 5:pii: 214.
- Lapchak PA, Zhang JH (2017) The high cost of stroke and stroke cytoprotection research. *Transl Stroke Res* 8:307-317.
- Lapchak PA, Zhang JH (2018) Translational stroke research guideline projections: the 20/20 standards. *Transl Stroke Res* 9:9-12.
- Lapchak PA, Schubert DR, Maher PA (2011) Delayed treatment with a novel neurotrophic compound reduces behavioral deficits in rabbit ischemic stroke. *J Neurochem* 116:122-131.
- Lapchak PA, Chapman DF, Nunez SY, Zivin JA (2000a) Dehydroepiandrosterone sulfate is neuroprotective in a reversible spinal cord ischemia model: possible involvement of GABA (A) receptors. *Stroke* 31:1953-1956.
- Lapchak PA, Araujo DM, Shackelford DA, Zivin JA (2000b) Prosaptide exacerbates ischemia-induced behavioral deficits in vivo; an effect that does not involve mitogen-activated protein kinase activation. *Neuroscience* 101:811-814.
- Lapchak PA, Araujo DM, Song D, Zivin JA (2001) Neuroprotection by the selective cyclooxygenase-2 inhibitor SC-236 results in improvements in behavioral deficits induced by reversible spinal cord ischemia. *Stroke* 32:1220-1225.
- Lapchak PA, Araujo DM, Weir CJ, Wei J, Zivin JA (2003) Effects of intrathecal administration of a cell permeant caspase inhibitor, boc-D-fluoromethylketone (BDFMK), on behavioral deficits following spinal cord ischemia: a dose-response analysis. *Brain Res* 959:183-190.
- Lapchak PA, Boitano PD, Bombien R, Cook DJ, Doyan S, Lara JM, Schubert DR (2019) CNB-001, a pleiotropic drug is efficacious in embolized agyrencephalic New Zealand white rabbits and ischemic gyrencephalic cynomolgus monkeys. *Exp Neurol* 313:98-108.
- Lapchak PA, KcKim, JM (2011) CeeTox™ analysis of CNB-001 a novel curcumin-based neurotrophic/neuroprotective lead compound to treat stroke: comparison with NXY-059 and Radicut. *Transl Stroke Res* 2:51-59.
- Lintott P, Hafez HM, Stansby G (1998) Spinal cord complications of thoracoabdominal aneurysm surgery. *Br J Surg* 85:5-15.
- Lipton SA (2005) The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism. *Curr Alzheimer Res* 2:155-165.
- Lipton SA (2006) Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. *Nat Rev Drug Discov* 5:160-170.
- Liu Y, Dargusch R, Maher P, Schubert D (2008) A broadly neuroprotective derivative of curcumin. *J Neurochem* 105:1336-1345.

- Maher P, Akaishi T, Schubert D, Abe K (2010) A pyrazole derivative of curcumin enhances memory. *Neurobiol Aging* 31:706-709.
- Min HK, Sung K, Yang JH, Kim WS, Jun TG, Lee YT, Park PW, Park BJ (2010) Can intraoperative motor-evoked potentials predict all the spinal cord ischemia during moderate hypothermic beating heart descending thoracic or thoraco-abdominal aortic surgery? *J Card Surg* 25:542-547.
- Miranda V, Sousa J, Mansilha A (2018) Spinal cord injury in endovascular thoracoabdominal aortic aneurysm repair: prevalence, risk factors and preventive strategies. *Int Angiol* 37:112-126.
- Nardone R, Pikija S, Mutzenbach JS, Seidl M, Leis S, Trinka E, Sellner J (2016) Current and emerging treatment options for spinal cord ischemia. *Drug Discov Today* 21:1632-1641.
- Ortmann SD, Hellenbrand DJ (2018) Glial cell line-derived neurotrophic factor as a treatment after spinal cord injury. *Neural Regen Res* 13:1733-1734.
- Panzhinskiy E, Hua Y, Lapchak PA, Topchiy E, Lehmann TE, Ren J, Nair S (2014) Novel curcumin derivative CNB-001 mitigates obesity-associated insulin resistance. *J Pharmacol Exp Ther* 349:248-257.
- Raiten J, Patel PA, Gutsche J (2015a) Management of postoperative atrial fibrillation in cardiac surgery patients. *Semin Cardiothorac Vasc Anesth* 19:122-129.
- Raiten JM, Ghadimi K, Augoustides JG, Ramakrishna H, Patel PA, Weiss SJ, Gutsche JT (2015b) Atrial fibrillation after cardiac surgery: clinical update on mechanisms and prophylactic strategies. *J Cardiothorac Vasc Anesth* 29:806-816.
- Rectenwald JE, Huber TS, Martin TD, Ozaki CK, Devidas M, Welborn MB, Seeger JM (2002) Functional outcome after thoracoabdominal aortic aneurysm repair. *J Vasc Surg* 35:640-647.
- Ruzicka J, Urdzikova LM, Svobodova B, Amin AG, Karova K, Dubisova J, Zaviskova K, Kubinova S, Schmidt M, Jhanwar-Uniyal M, Jendelova P (2018) Does combined therapy of curcumin and epigallocatechin gallate have a synergistic neuroprotective effect against spinal cord injury? *Neural Regen Res* 13:119-127.
- Sámano C, Nistri A (2019) Mechanism of neuroprotection against experimental spinal cord injury by riluzole or methylprednisolone. *Neurochem Res* 44:200-213.
- Sharma S, Ying Z, Gomez-Pinilla F (2010) A pyrazole curcumin derivative restores membrane homeostasis disrupted after brain trauma. *Exp Neurol* 226:191-199.
- Shaw PJ (1986) Neurological complications of cardiovascular surgery: II. Procedures involving the heart and thoracic aorta. *Int Anesthesiol Clin* 24:159-200.
- Sirlak M, Eryilmaz S, Bahadır Inan M, Sirin YS, Besalti O, Yazicioglu L, Ozcinar E, Erdemli E, Tasoş R, Elhan AH, Kaya B, Ozyurda U (2008) Effects of carbamazepine on spinal cord ischemia. *J Thorac Cardiovasc Surg* 136:1038-1043.
- Skillman JJ (1986) Neurological complications of cardiovascular surgery: I. Procedures involving the carotid arteries and abdominal aorta. *Int Anesthesiol Clin* 24:135-157.
- Springer JE, Prajapati P, Sullivan PG (2018a) Targeting the mitochondrial permeability transition pore in traumatic central nervous system injury. *Neural Regen Res* 13:1338-1341.
- Springer JE, Visavadiya NP, Sullivan PG, Hall ED (2018b) Post-injury treatment with NIM811 promotes recovery of function in adult female rats after spinal cord contusion: a dose-response study. *J Neurotrauma* 35:492-499.
- STAIR (1999) Recommendations for standards regarding preclinical neuroprotective and restorative drug development. *Stroke* 30:2752-2758.
- Stern JR, Sun T, Mao J, Sedrakyan A, Meltzer AJ (2019) A decade of thoracic endovascular aortic aneurysm repair in New York state: volumes, outcomes, and implications for the dissemination of endovascular technology. *Ann Vasc Surg* 54:123-133.
- Svensson LG (2005) Paralysis after aortic surgery: in search of lost cord function. *Surgeon* 3:396-405.
- Svensson LG, Khitin L, Nadolny EM, Kimmel WA (2003) Systemic temperature and paralysis after thoracoabdominal and descending aortic operations. *Arch Surg* 138:175-180.
- Tarlov IM (1954) Spinal cord compression studies. III. Time limits for recovery after gradual compression in dogs. *AMA Arch Neurol Psychiatry* 71:588-597.
- Tarlov IM (1955) Spinal cord injuries; early treatment. *Surg Clin North Am New York No.*:591-607.
- Tarlov IM (1972) Acute spinal cord compression paralysis. *J Neurosurg* 36:10-20.
- Tarlov IM, Klinger H (1954) Spinal cord compression studies. II. Time limits for recovery after acute compression in dogs. *AMA Arch Neurol Psychiatry* 71:271-290.
- Tarlov IM, Herz E (1954) Spinal cord compression studies. IV. Outlook with complete paralysis in man. *AMA Arch Neurol Psychiatry* 72:43-59.
- Tarlov IM, Klinger H, Vitale S (1953) Spinal cord compression studies. I. Experimental techniques to produce acute and gradual compression. *AMA Arch Neurol Psychiatry* 70:813-819.
- Terada H, Kazui T, Yamashita K, Washiyama N, Suzuki K, Suzuki T, Okura K, Suzuki M (2004) Spinal cord protection and operative results of the thoracoabdominal aortic aneurysm. *Kyobu Geka* 57:307-312.
- Tsuji O, Sugai K, Yamaguchi R, Tashiro S, Nagoshi N, Kohyama J, Iida T, Ohkubo T, Itakura G, Isoda M, Shinozaki M, Fujiyoshi K, Kanemura Y, Yamanaka S, Nakamura M, Okano H (2019) Concise review: laying the groundwork for a first-in-human study of an induced pluripotent stem cell-based intervention for spinal cord injury. *Stem Cells* 37:6-13.
- Uchida N (2014) How to prevent spinal cord injury during endovascular repair of thoracic aortic disease. *Gen Thorac Cardiovasc Surg* 62:391-397.
- Ullery BW, Wang GJ, Low D, Cheung AT (2011a) Neurological complications of thoracic endovascular aortic repair. *Semin Cardiothorac Vasc Anesth* 15:123-140.
- Ullery BW, Cheung AT, Fairman RM, Jackson BM, Woo EY, Bavaria J, Pochettino A, Wang GJ (2011b) Risk factors, outcomes, and clinical manifestations of spinal cord ischemia following thoracic endovascular aortic repair. *J Vasc Surg* 54:677-684.
- Ullery BW, Quatromoni J, Jackson BM, Woo EY, Fairman RM, Desai ND, Bavaria JE, Wang GJ (2011c) Impact of intercostal artery occlusion on spinal cord ischemia following thoracic endovascular aortic repair. *Vasc Endovascular Surg* 45:519-523.
- Valera E, Dargusch R, Maher PA, Schubert D (2013) Modulation of 5-lipoxygenase in proteotoxicity and Alzheimer's disease. *J Neurosci* 33:10512-10525.
- Waterford SD, Rastegar M, Goodwin E, Lapchak PA, Juan V, Haji F, Bombien R, Khoynzhad A (2015) Methodology of motor evoked potentials in a rabbit model. *Transl Stroke Res* 6:399-406.
- Wu A, Ying Z, Schubert D, Gomez-Pinilla F (2011) Brain and spinal cord interaction: a dietary curcumin derivative counteracts locomotor and cognitive deficits after brain trauma. *Neurorehabil Neural Repair* 25:332-342.
- Xie BC, Wang QH, Xu ZM, Zhou CH, Wu JH, Xu DH (2018) Efficacy and safety of stem cell transplantation for spinal cord injury. *Minerva Med* 109:336-337.
- Zhang F (2018) Structure-function evaluation of stem cell therapies for spinal cord injury. *Curr Stem Cell Res Ther* 13:202-214.
- Zhang Q, Zhang LX, An J, Yan L, Liu CC, Zhao JJ, Yang H (2018) Huangqin flavonoid extraction for spinal cord injury in a rat model. *Neural Regen Res* 13:2200-2208.
- Zhu Y, Uezono N, Yasui T, Nakashima K (2018) Neural stem cell therapy aiming at better functional recovery after spinal cord injury. *Dev Dyn* 247:75-84.

P-Reviewers: Tashiro S, Vizuete A; C-Editor: Zhao M; S-Editor: Li CH; L-Editor: Song LP; T-Editor: Jia Y